Compare Degarelix (evidence A) and Kisspeptin (evidence C) on mechanism, clinical status, safety, and dosing.
Degarelix is a synthetic GnRH antagonist (MW ~1632.3 g/mol) and the first injectable GnRH receptor blocker approved for advanced prostate cancer. FDA-approved…
Kisspeptin is an endogenous neuropeptide encoded by the KISS1 gene that plays a critical role in regulating reproductive hormone secretion. It binds GPR54…
Full profiles: Degarelix, Kisspeptin.